Advancing Psoriasis Care: A Clinical Call to Action

Rethinking Psoriasis: A Complex Inflammatory Disorder

Psoriasis affects approximately 8 million Americans and up to 3% of the global population [1]. More than a skin condition, psoriasis is a systemic inflammatory disease with links to:
• Psoriatic arthritis (PsA): Present in up to 30–40% of patients [2]
• Cardiometabolic risk: Increased incidence of obesity, diabetes, hypertension, and cardiovascular disease [3,4]
• Psychiatric comorbidities: Elevated rates of depression, anxiety, and suicidality [5]
Without early intervention, patients may experience irreversible joint damage, worsening systemic inflammation, and significant declines in quality of life.

Key Strategies to Advance Psoriasis Care

This July, Hyperpigmentation and Melasma Awareness Month reminds us that managing pigmentary disorders requires nuanced clinical judgment, long-term patient support, and culturally aware, competent care. Below are 5 key pillars to help us provide the best possible care for our patients suffering with these conditions.

1. Prioritize Early Diagnosis and Screening

Early recognition and diagnosis, especially of PsA, can prevent long-term damage and disability. The PEST (Psoriasis Epidemiology Screening Tool) is a simple, validated questionnaire used to identify PsA in primary care and dermatology settings [6].
Recommendation: Screen psoriasis patients for joint pain, stiffness, swelling, and fatigue at every visit.

2. Embrace a Multidisciplinary Model

Collaborative care models improve outcomes by addressing both cutaneous and systemic aspects of the disease. Dermatologists, rheumatologists, primary care physicians, cardiologists, mental health professionals, and nutritionists all play a role in care coordination.
• AAD/NPF guidelines support an integrated approach to managing moderate-to-severe disease [7].
• Rheumatology referral should be timely when PsA is suspected.

3. Personalize and Optimize Treatment

Advances in biologic and targeted therapies (e.g., TNF inhibitors, IL-17 and IL-23 inhibitors, JAK inhibitors) allow for individualized care based on disease severity, patient history, and comorbidities.
Clinical insight: Biologics have demonstrated PASI 75–100 response rates and long-term safety in large trials [8,9].
• Use shared decision-making to align therapy with patient goals.
• Reassess treatment efficacy and tolerability every 3–6 months.

4. Address Psychosocial and Functional Impairment

Psoriasis significantly impairs emotional and social well-being, even when physical symptoms are mild.
• Use tools like the Dermatology Life Quality Index (DLQI) to assess impact.
• Screen for depression using the PHQ-9, and refer to mental health services when needed [10].

5. Promote Lifestyle Interventions

Modifiable risk factors such as smoking, alcohol use, obesity, and inactivity contribute to disease severity and comorbidity burden [11].
Counsel patients on:
• Weight reduction to improve treatment response
• Anti-inflammatory diets (e.g., Mediterranean)
• Cardiovascular risk management
• Smoking cessation and alcohol moderation

Clinical Practice Pearls

✅ Early joint screening prevents irreversible damage
✅ Lifestyle counseling is as critical as pharmacologic therapy
✅ Monitor comorbidities and lab parameters regularly
✅ Communicate with empathy—stigma and isolation are common

Keeping Up with Innovation

Professional development and evidence-based updates are essential for delivering cutting-edge care. Here are several recommended resources:
• National Psoriasis Foundation (NPF) – Guidelines, CME, and tools
• American Academy of Dermatology (AAD) – Clinical practice guidelines
• GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis)

Conclusion: Progress Requires Action

To truly advance psoriasis care, clinicians must shift from reactive to proactive, systemic management. By integrating diagnostics, personalized treatment, and interdisciplinary collaboration, we can reduce disease burden and elevate patient outcomes.

References

1. National Psoriasis Foundation. Psoriasis Statistics. https://www.psoriasis.org
   2. Mease PJ, et al. “Prevalence of Psoriatic Arthritis in Patients With Psoriasis.” J Am Acad Dermatol. 2013;69(5):729–735.
   3. Takeshita J, et al. “Psoriasis and comorbid diseases: Epidemiology.” J Am Acad Dermatol. 2017;76(3):377–390.
   4. Gelfand JM, et al. “Risk of myocardial infarction in patients with psoriasis.” JAMA. 2006;296(14):1735–1741.
   5. Kurd SK, Gelfand JM. “The prevalence of previously diagnosed and undiagnosed psoriasis in US adults.” J Am Acad Dermatol. 2009;60(2):218–224.
   6. Ibrahim GH, et al. “Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new tool: the PEST questionnaire.” Br J Dermatol. 2009;161(3):474–480.
   7. Elmets CA, et al. “Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.” J Am Acad Dermatol. 2019;80(4):1029–1072.
   8. Reich K, et al. “Secukinumab induction and maintenance therapy in moderate-to-severe psoriasis.” Lancet. 2015;386(9993):1311–1320.
   9. Gordon KB, et al. “Efficacy and safety of guselkumab in moderate-to-severe psoriasis: Results from VOYAGE 1 and 2.” Lancet. 2017;389(10066):2287–2301.
   10. Fleming P, et al. “The prevalence of anxiety in patients with psoriasis: A systematic review and meta-analysis.” J Eur Acad Dermatol Venereol. 2017;31(5):798–807.
   11. Armstrong AW, et al. “Obesity and severity of psoriasis: a systematic review and meta-analysis.” J Invest Dermatol. 2012;132(9):2196–2203.

#PsoriasisCare #PsoriaticDisease #Dermatology #Rheumatology #InflammatoryDisease
#ChronicDiseaseManagement #PsoriaticArthritis #BiologicTherapy #HealthcareLeadership #ClinicalEducation#InterdisciplinaryCare #PatientCenteredCare #AutoimmuneDisease #MentalHealthInChronicIllness #EvidenceBasedMedicine